Head to Head Analysis: PhaseBio Pharmaceuticals (NASDAQ:PHAS) Vs. Alpine Immune Sciences (NASDAQ:ALPN)
Head to Head Analysis: PhaseBio Pharmaceuticals (NASDAQ:PHAS) Vs. Alpine Immune Sciences (NASDAQ:ALPN)
PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) and Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.
相生物製藥(納斯達克：PHAS-GET評級)和高山免疫科學(納斯達克：ALPN-GET評級)都是小盤醫療公司，但哪種投資更好？我們將根據這兩家公司的風險、估值、機構所有權、分析師建議、收益、盈利能力和股息等方面的實力進行比較。
Institutional & Insider Ownership
機構與內部人持股
49.0% of PhaseBio Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Alpine Immune Sciences shares are held by institutional investors. 9.9% of PhaseBio Pharmaceuticals shares are held by insiders. Comparatively, 54.7% of Alpine Immune Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
PhaseBio PharmPharmticals 49.0%的股份由機構投資者持有。相比之下，阿爾卑斯免疫科學公司79.0%的股份由機構投資者持有。PhaseBio PharmPharmticals 9.9%的股份由內部人士持有。相比之下，阿爾卑斯免疫科學公司54.7%的股份由內部人士持有。強大的機構持股表明，捐贈基金、大型基金經理和對衝基金相信，從長期來看，一隻股票的表現將好於大盤。
Profitability
盈利能力
This table compares PhaseBio Pharmaceuticals and Alpine Immune Sciences' net margins, return on equity and return on assets.
此表比較了PhaseBio製藥公司和阿爾卑斯免疫科學公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| PhaseBio Pharmaceuticals | -12,572.13% | N/A | -174.38% |
| Alpine Immune Sciences | -169.82% | -47.34% | -23.12% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| PhaseBio製藥公司 | -12,572.13% | 不適用 | -174.38% |
| 阿爾卑斯山免疫科學 | -169.82% | -47.34% | -23.12% |
Analyst Recommendations
分析師建議
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PhaseBio Pharmaceuticals | 0 | 5 | 0 | 0 | 2.00 |
| Alpine Immune Sciences | 0 | 0 | 3 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| PhaseBio製藥公司 | 0 | 5 | 0 | 0 | 2.00 |
| 阿爾卑斯山免疫科學 | 0 | 0 | 3 | 0 | 3.00 |
PhaseBio Pharmaceuticals currently has a consensus target price of $4.50, suggesting a potential upside of 4,636.84%. Alpine Immune Sciences has a consensus target price of $15.67, suggesting a potential upside of 157.68%. Given PhaseBio Pharmaceuticals' higher probable upside, equities analysts clearly believe PhaseBio Pharmaceuticals is more favorable than Alpine Immune Sciences.
PhaseBio製藥公司目前的共識目標價為4.50美元，這意味着潛在的上漲幅度為4636.84%。阿爾卑斯免疫科學公司的共識目標價為15.67美元，暗示潛在上漲157.68%。鑑於PhaseBio製藥公司更有可能上行，股票分析師顯然認為PhaseBio製藥公司比阿爾卑斯免疫科學公司更有利。
Risk and Volatility
風險和波動性
PhaseBio Pharmaceuticals has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500. Comparatively, Alpine Immune Sciences has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.
PhaseBio PharmPharmticals的貝塔係數為2.87，這表明其股價的波動性比標準普爾500指數高187%。相比之下，阿爾卑斯山免疫科學公司的貝塔係數為1.5，這表明其股價的波動性比標準普爾500指數高50%。
Valuation & Earnings
估值與收益
This table compares PhaseBio Pharmaceuticals and Alpine Immune Sciences' gross revenue, earnings per share (EPS) and valuation.
此表比較了PhaseBio製藥公司和阿爾卑斯免疫科學公司的毛收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PhaseBio Pharmaceuticals | $10.83 million | 0.44 | -$131.07 million | ($2.13) | -0.04 |
| Alpine Immune Sciences | $23.44 million | 7.89 | -$50.33 million | ($1.92) | -3.17 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| PhaseBio製藥公司 | 1083萬美元 | 0.44 | -1.3107億美元 | ($2.13) | -0.04 |
| 阿爾卑斯山免疫科學 | 2344萬美元 | 7.89 | -5,033萬元 | ($1.92) | -3.17 |
Alpine Immune Sciences has higher revenue and earnings than PhaseBio Pharmaceuticals. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than PhaseBio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
阿爾卑斯免疫科學公司的收入和收益高於PhaseBio製藥公司。阿爾卑斯免疫科學的市盈率低於PhaseBio PharmPharmticals，這表明它目前是兩隻股票中更負擔得起的一隻。
Summary
摘要
Alpine Immune Sciences beats PhaseBio Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
阿爾卑斯免疫科學公司在兩隻股票之間的14個因素中有10個超過了PhaseBio製藥公司。
About PhaseBio Pharmaceuticals
關於PhaseBio製藥公司
(Get Rating)
(獲取評級)
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
PhaseBio製藥公司是一家臨牀階段的生物製藥公司，致力於心血管疾病新療法的開發和商業化。該公司正在籌備中的藥物包括：用於抗血小板治療替卡格雷的新型逆轉藥bentracimab(PB2452)，用於治療肺動脈高壓的每週一次的血管活性腸肽受體激動劑pemziviptadil(PB1046)，以及用於治療頑固性高血壓的口服藥物PB6440。該公司由阿舒託什·奇爾科蒂和克萊·貝爾納丁·索普於2002年1月創立，總部設在賓夕法尼亞州馬爾文。
About Alpine Immune Sciences
關於阿爾卑斯免疫科學
(Get Rating)
(獲取評級)
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
阿爾卑斯免疫科學公司是一家臨牀階段的生物製藥公司，專注於發現和開發基於蛋白質的免疫療法，用於治療癌症、自身免疫/炎症性疾病和其他疾病。其產品線包括用於治療自身免疫和炎症性疾病的可誘導T細胞共刺激因子(ICOS)/分化簇28(CD28)拮抗劑計劃ALPN-101；用於治療癌症的條件性CD28共刺激因子和雙重檢查點抑制劑ALPN-202；以及用於治療B細胞介導性炎症和自身免疫性疾病的雙重B細胞細胞因子拮抗劑ALPN-303。該公司與AbbVie愛爾蘭無限公司簽署了開發ALPN-101的合作協議，並與Adaptimmune Treateutics plc達成了開發下一代Spear T細胞產品的合作協議。阿爾卑斯免疫科學公司成立於2007年，總部設在華盛頓州西雅圖。
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得PhaseBio製藥日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對PhaseBio製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。